Its pioneering LAESI DP-1000 Direct Ionization System is set to be a key enabling technology for breakthroughs in research, diagnostics and medicine
MOUNTAIN VIEW, Calif. - July 17, 2012 - Based on its recent analysis of the bioanalytics market, Frost & Sullivan recognizes Protea Biosciences Group, Inc. with the 2012 North American Frost & Sullivan Award for New Product Innovation for the LAESI DP-1000. This instrument is the first to allow in vivo mass spectrometry (MS) applications and positions Protea at the forefront of technology-enablers for novel scientific discoveries.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
Protea - which provides bioanalytical products and services for the life sciences and biochemical markets - secured an exclusive worldwide licensing agreement with George Washington University for commercial rights to Laser Ablation Electrospray Ionization (LAESI) MS technology in September 2008. This technology enables the direct identification of molecules of interest in biological samples and provides information on their distribution profile. In 2012, the firm launched the LAESI DP-1000 Direct Ionization System as both an off-the-shelf instrument and a service, allowing a broad base of the scientific community to gain access to the technology.
"With an expanding line of service offerings and growing awareness of the LAESI DP-1000, Protea Biosciences has emerged as a significant player in bioanalytics and an enabler of major scientific breakthroughs," said Frost & Sullivan Sr. Industry Analyst Christi Bird. "The LAESI DP-1000 system greatly improves the efficiency of biological investigations, allowing scientists to better understand the mechanics of a pathology and the effects of drug and target interaction."
Furthermore, with the capability to ionize native samples, the LAESI DP-1000 analyzes living cells and tissues in their natural environment, which provides precise and significant data on biological states. This allows researchers to accurately answer biological questions concerning the molecular events of live cells and tissues, a truly market-changing capability. These novel applications make the LAESI DP-1000 a highly innovative and powerful instrument.
The speed of data acquisition using the LAESI platform workflow allows for both spatial and dynamic mapping of biomolecules. With applications in the fields of pharmaceutical and biological research, surgical and molecular pathology, clinical diagnostics, chemical and biological defense, forensics, and food safety, Protea is primed for significant growth as researchers become familiar with the benefits of LAESI-MS technology.
"By offering access to the LAESI DP-1000 technology, both as an off-the-shelf instrument and as a service, Protea provides researchers the opportunity to choose their R&D investments under the financial terms that better fit their needs," noted Bird. "This has proved a fruitful method for Protea to expand brand awareness and cultivate a strong reputation for its capabilities."
For its commitment to innovation and enabling a better understanding of the biological and chemical world, Frost & Sullivan is pleased to present the 2012 North America Product Innovation Award for bioanalytics to Protea Biosciences.
Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which increases customer acquisition and overall market penetration potential.
About Protea Biosciences Group, Inc.
Protea is a leader in the field of bioanalytics, the identification and analysis of proteins and other biomolecules that are produced by living cells - technology that is essential to pharmaceutical, medical and life science research.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
P: 210. 247.3870